检索结果-南通市图书馆

Clinical Trial of Measles and Rubella Combined vaccine Produced by POLYVAC in Vietnam

在线全文

学校读者我要写书评

暂无评论

Open Journal of Pediatrics 2018年第2期8卷 178-188页

作者： Nguyen Dang Hien Nguyen Thuy Huong Ngo Thu Huong Pham Thi Phuong Thao Dinh Hong Duong Nguyen Xuan Dong Tomio Lee Takashi Ito Tetsuo Nakayama Center for Research and Production of vaccines and Biologicals (POLYVAC) Hanoi Vietnam Military Academy of Medicine Hanoi Vietnam kitasato vaccine plant Kitasato Daiichi Sankyo Vaccine Saitama Japan Laboratory of Viral Infection I Kitasato Institute for Life Sciences Tokyo Japan

A clinical trial of measles and rubella combined vaccine (MR: MRVAC) produced by POLYVAC was conducted in Vietnam in 2016. A total of 756 subjects were enrolled, and 504 were allocated to MRVAC and 252 to control MR vaccine groups. Paired sera were obtained in 733, and the number of subjects was 403 aged 1 - 2 years, 164 aged 2 - 18 years, and 166 aged 18 - 45 years. Antibodies against measles and rubella viruses were evaluated by EIA. Most subjects had been immunized with a single dose of Expanded Programme on Immunization (EPI) measles vaccine at 9 months of age. Only 41 of 403 subjects aged 1 - 2 years were negative for measles antibody before vaccination, and all became seroconverted. A serological response of more than a 2-fold increase against measles was noted in 214 (47%, 95% CI;42.4% - 51.6%) of 458 initially seropositive individuals immunized with MRVAC and 65 (28%, 95% CI;22.3% - 33.8%) of 234 in the control group, and geometric mean titer (GMT) after vaccination was 25.49-5.60 in MRVAC and 25.03-5.24 in control group. Seroconversion against rubella virus after immunization with MRVAC was noted in 267 (98.5%, 95% CI;97.1% - 100%) of 271 initially seronegative subjects, similar to that after immunization with control group. GMT after immunization with MRVAC was 24.88-5.11 significantly lower than that after immunization with control vaccine (25.59-5.80). Most subject ≥ 2 years of age had rubella antibody because of MR vaccination campaign and no significant serological response was observed in initially seronegatives. MRVAC was highly immunogenic and safe vaccine and the domestic production of MR vaccine would contribute to realizing the goal of eliminating measles and rubella.

关键词： Measles vaccine Rubella vaccine MR Combined vaccine Elimination of Measles and Rubella

Bacterial and cancerous cell membrane fused liposome coordinates with PD-L1 inhibitor for cancer immunotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nano Research 2024年第9期17卷 8389-8401页

作者： Xianjin Luo Chenglong Li Zhaofei Guo Hairui Wang Penghui He Yuanhao Zhao Yi Lin Chunting He Yingying Hou Yongshun Zhang Guangsheng Du Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial TechnologyWest China School of PharmacySichuan UniversityChengdu 610064China Pharmaceutical Biotechnology Department of PharmacyLMU MunichButenandt Strasse 5-13Munich 81377Germany Department of Biomedical Engineering College of Future TechnologyPeking UniversityBeijing 100871China

Although tumor cell membranes with broad-spectrum antigens have been explored for cancer vaccines for decades,their relatively poor capacity to stimulate immune responses,especially cellular immune responses,has limited their ***,we presented a novel bacterial and cancerous cell membrane fusogenic liposome for co-delivering cell membrane-derived antigens and ***,a programmed death-ligand 1(PD-L1)inhibitor,JQ-1,was incorporated into the formulation to tackle the up-regulated PD-L1 expression of antigen-presenting cells(APCs)upon vaccination,thereby augmenting its anti-tumor *** fusogenic liposomes demonstrated significantly improved cellular uptake by APCs and effectively suppressed PD-L1 expression in bone marrow-derived dendritic cells(BMDCs)in *** subcutaneous vaccination,the nano-vaccines efficiently drained to the tumor-draining lymph nodes(TDLNs),and significantly inhibited PD-L1 expression of both dendritic cells(DCs)and macrophages within the TDLNs and *** a result,the liposomal vaccine induced robust innate and cellular immune responses and inhibited tumor growth in a colorectal carcinoma-burden mouse *** summary,the fabricated cell membrane-based fusogenic liposomes offer a safe,effective,and easily applicable strategy for tumor immunotherapy and hold potential for personalized cancer immunotherapy.

关键词： fusogenic liposome tumor cell membrane adjuvant programmed death-ligand 1(PD-L1)inhibitor tumor draining lymph nodes

Insights into therapeutic peptides in the cancerimmunity cycle:Update and challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2024年第9期14卷 3818-3833页

作者： Xiaokun Zhang Ye Wu Jiayi Lin Shengxin Lu Xinchen Lu Aoyu Cheng Hongzhuan Chen Weidong Zhang Xin Luan Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology Institute of Interdisciplinary Integrative Medicine Research and Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 201203China Institute of Medicinal plant Development Chinese Academy of Medical Science&Peking Union Medical CollegeBeijing 100193China School of Pharmacy Second Military Medical UniversityShanghai 200433China Department of Pharmacology School of PharmacyFudan UniversityShanghai 201203China

Immunotherapies hold immense potential for achieving durable potency and long-term survival opportunities in cancer *** vital biological mediators,peptides with high tissue penetration and superior selectivity offer significant promise for enhancing cancer immunotherapies(CITs).However,physicochemical peptide features such as conformation and stability pose challenges to their on-target *** review provides a comprehensive overview of recent advancements in therapeutic peptides targeting key steps of the cancer-immunity cycle(CIC),including tumor antigen presentation,immune cell regulation,and immune checkpoint *** attention is given to the opportunities and challenges associated with these peptides in boosting CIC within the context of clinical ***,possible future developments in this field are also discussed to provide insights into emerging CITs with robust efficacy and safety profiles.

关键词： Cancer-immunity cycle Oncolytic peptide Peptide neoantigen vaccine Peptide mimotope Immune checkpoint blockade Cancer immunotherapy Synthetic long peptide vaccine Peptide-major histocompatibility complex

Fighting Ebola with ZMapp: spotlight on plant-made antibody

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2014年第10期57卷 987-988页

作者： ZHANG YunFang LI DaPeng JIN Xia HUANG Zhong vaccine Research Center Institut Pasteur of Shanghai Chinese Academy of Sciences

Currently,a large Ebola endemic is ongoing in West *** to the World Health Organization,as of August19,the viral outbreak has led to 2240 suspected and confirmed cases and 1229 deaths in four countries:Guinea,Liberia,... 详细信息

关键词：聚光灯疾病预防控制中心战斗抗体制造植物世界卫生组织利比里亚

Proteomic Analysis of Bovine Nucleolus

在线全文

学校读者我要写书评

暂无评论

Genomics, Proteomics & Bioinformatics 2010年第3期8卷 145-158页

作者： Amrutlal K.Patel Doug Olson Suresh K.Tikoo vaccine and Infectious Disease Organization University of Saskatchewan Department of Veterinary Microbiology Western College of Veterinary Medicine University of Saskatchewan National Research Council Plant Biotechnology Institute University of Saskatchewan School of Public Health University of Saskatchewan

Nucleolus is the most prominent subnuclear structure, which performs a wide variety of functions in the eukaryotic cellular processes. In order to understand the structural and functional role of the nucleoli in bovine cells, we analyzed the proteomic composition of the bovine nucleoli. The nucleoli were isolated from Madin Darby bovine kidney cells and subjected to proteomic analysis by LC-MS/MS after fractionation by SDS-PAGE and strong cation exchange chromatography. Analysis of the data using the Mascot database search and the GPM database search identified 311 proteins in the bovine nucleoli, which contained 22 proteins previously not identified in the proteomic analysis of human nucleoli. Analysis of the identified proteins using the GoMiner software suggested that the bovine nucleoli contained proteins involved in ribosomal biogenesis, cell cycle control, transcriptional, translational and post-translational regulation, transport, and structural organization.

关键词： bovine nucleolus proteomics 1D SDS-PAGE SCX LC-MS/MS

Protection of Mice with a Divalent Tuberculosis DNA vaccine Encoding Antigens Ag85B and MPT64

在线全文

学校读者我要写书评

暂无评论

Acta Biochimica et Biophysica Sinica 2004年第4期36卷 269-276页

作者： Xia TIAN, Hong CAI, and Yu-Xian ZHU* The National Laboratory of Protein Engineering and plant Genetic Engineering, Peking University, Beijing 100871, China The National Laboratory of Protein Engineering and plant Genetic Engineering Peking UniversityBeijing 100871 China

DNA vaccine may be a promising tool for controlling tuberculosis development. However, vaccines encoding single antigens of mycobacterium did not produce protective effect as BCG did. In the present study, we evaluated the immunogenicity and protective efficacy of a divalent DNA vaccine encoding two immunodominant antigens Ag85B and MPT64 of Mycobacterium tuberculosis. We found that both humoral and Th1-type (high IFN-γ, low IL-4) cellular responses obtained from the divalent DNA vaccine group were significantly higher than that conferred by BCG. RT-PCR results showed that antigens were expressed differentially in various organs in divalent DNA vaccine group. The survival rate for mice treated with the divalent DNA vaccine after challenging with high doses of virulent M. tuberculosis H37Rv was significantly higher than that of the BCG group or any of the single DNA vaccine group. Significant differ- ences were also found between the single and divalent DNA vaccinated mice in terms of body, spleen and lung weight. Bacterial loading decreased about 2000-fold in lungs and about 100-fold in spleens of divalent DNA vaccinated mice when compared with that of the control group. We conclude that our divalent DNA vaccine may be a better choice for controlling tuberculosis disease in animals.

关键词： tuberculosis divalent DNA vaccine immunogenicity protection

Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy:a novel delivery system candidate for tumor vaccines

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2024年第4期67卷 680-697页

作者： Nan Li Yun Zhang Miaomiao Han Tian Liu Jinjia Wu Yingxia Xiong Yikai Fan Fan Ye Bing Jin Yinghua Zhang Guibo Sun Xiaobo Sun Zhengqi Dong State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs Chinese Academy of Medical Sciences&Peking Union Medical College(CAMS)Institute of Medicinal Plant Development(IMPLAD)Beijing 100193China Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine from Ministry of Education Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine(Natural Medicine)and Translational MedicineKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription from Chinese Academy of Medical SciencesCAMSIMPLADBeijing 100193China Department of Pharmaceutics School of Pharmaceutical SciencesHeilongjiang University of Chinese MedicineHarbin 150036China Jilin Academy of Chinese Medicine Sciences Changchun 130012China Joint Research Center for Chinese Medicinal Herbs IMPLADABRC&ACCLBeijing 100193China

The study of tumor nanovaccines(NVs)has gained interest because they specifically recognize and eliminate tumor ***,the poor recognition and internalization by dendritic cells(DCs)and insufficient immunogenicity restricted the vaccine ***,we extracted two molecular-weight Astragalus polysaccharides(APS,12.19 k D;APSHMw,135.67 k D)from Radix Astragali and made them self-assemble with OVA257–264directly forming OVA/APS integrated nanocomplexes through the microfluidic *** nanocomplexes were wrapped with a sheddable calcium phosphate layer to improve *** in the formed nanocomplexes served as drug carriers and immune adjuvants for potent tumor *** optimal APS-NVs were approximately 160 nm with uniform size distribution and could remain stable in physiological saline *** FITC-OVA in APS-NVs could be effectively taken up by DCs,and APS-NVs could stimulate the maturation of DCs,improving the antigen cross-presentation efficiency in *** possible mechanism was that APS can induce DC activation via multiple receptors such as dectin-1 and Toll-like receptors 2 and *** accumulation of APS-NVs both in draining and distal lymph nodes were observed following *** APS-NVs could easily access the lymph ***,APS-NVs could markedly promote antigen delivery efficiency to DCs and activate cytotoxic T *** addition,APS-NVs achieve a better antitumor effect in established B16-OVA melanoma tumors compared with the OVA+Alum treatment *** antitumor mechanism correlated with the increase in cytotoxic T cells in the tumor ***,the poor tumor inhibitory effect of APS-NVs on the nude mouse model of melanoma also confirmed the participation of antitumor adaptive immune response induced by ***,this study developed a promising APS-based tumor NV that is an efficient tumor immunotherapy without systemic side effects.

关键词： Astragalus polysaccharides nanovaccines OVA immunotherapy self-adjuvant

Chikungunya infection:A potential re-emerging global threat

在线全文

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Medicine 2016年第10期9卷 910-915页

作者： Shanmugaraj Bala Murugan Ramalingam Sathishkumar plant Genetic Engineering Laboratory Department of BiotechnologyBharathiar University

Infectious diseases are indeed a lifelong threat to everyone irrespective of age, sex, lifestyle and socio-economic status. The infectious diseases have persisted among the prominent causes of death globally. Recently, re-emergence of Chikungunya viral infection harmed many in Asian and African countries. Chikungunya was considered as a major threat in developing and underdeveloped countries; the recent epidemiological outbreak of Chikungunya in La Reunion urges the global researchers to develop effective vaccine against this viral disease. In this review, Chikungunya, pathogenesis and epidemiology were briefly described.

关键词： Aedes mosquitoes Alphavirus Arthropod-borne disease Chikungunya Non-Structural Proteins Structural Proteins

plant-produced recombinant SARS-CoV-2 receptor-binding domain;an economical,scalable biomaterial source for COVID-19 diagnosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomaterials Translational 2021年第1期2卷 43-49页

作者： Kaewta Rattanapisit Gorawit Yusakul Balamurugan Shanmugaraj Kittinop Kittirotruji Phassorn Suwatsrisakul Eakachai Prompetchara Suthira Taychakhoonavud Waranyoo Phoolcharoen Baiya Phytopharm Co. Ltd.BangkokThailand School of Pharmacy Walailak UniversityNakhon Si ThammaratThailand Centre of Excellence in vaccine Research and Development(Chula vaccine Research Centre Chula VRC)Faculty of MedicineChulalongkorn UniversityBangkokThailand Department of Laboratory Medicine Faculty of MedicineChulalongkorn UniversityBangkokThailand Department of Social and Administrative Pharmacy Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand Research Unit for plant-produced Pharmaceuticals Chulalongkorn UniversityBangkokThailand Department of Pharmacognosy and Pharmaceutical Botany Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand

The outbreak of the novel coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),spread rapidly causing a severe global health *** standard COVID-19 diagnosis relies heavily on molecular tests to detect viral RNA in patient samples;however,this method is costly,requires highly-equipped laboratories,multiple reagents,skilled laboratory technicians,and takes 3-6 hours to *** overcome these limitations,we developed a plant-based production platform for the SARS-CoV-2 receptor-binding domain as an economical source of detection reagents for a lateral-flow immunoassay strip(LFIA)which is suitable for detection of IgM/IgG antibodies in human ***,we validated the plant-produced SARS-CoV-2 receptor-binding domain-based LFIA as a useful diagnostic tool for COVID-19.A total of 51 confirmed COVID-19 serum samples were tested using the LFIA,and the obtained results were consistent with those from polymerase chain reaction assays,while providing sensitivity and specificity of 94.1%and 98%,*** developed LFIA is rapid,scalable,user-friendly,and relatively inexpensive with a simple test procedure,making it useful for the routine monitoring of COVID-19 in clinical *** study was approved on March 19,2020 by the Ethics Committee of the Faculty of Medicine,Chulalongkorn University(COA No.354/2020 and IRB No.236/63).

关键词： COVID-19 lateral flow immunoassay Nicotiana benthamiana point-of-care testing recombinant protein SARS-CoV-2